Alterations of motor cortical excitability and anatomy in unverricht-lundborg disease

Movement Disorders

Volumn 28, Issue 13, 2013, Pages 1860-1867

  Danner, Nils ^a,b   Julkunen, Petro ^b   Hyppönen, Jelena ^b   Niskanen, Eini ^a,b   Säisänen, Laura ^a,b   Könönen, Mervi ^b   Koskenkorva, Päivi ^b   Vanninen, Ritva ^a,b   Kälviäinen, Reetta ^a,b   Mervaala, Esa ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

EPM1; Progressive myoclonus epilepsy; Transcranial magnetic stimulation motor cortex; Unverricht Lundborg disease

Indexed keywords

CLOBAZAM; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; PIRACETAM; TOPIRAMATE; VALPROIC ACID;

ADULT; AMPLIFIER; ARTICLE; CEREBELLAR STIMULATOR; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICAL ELECTRIC FIELD; DISEASE DURATION; DISEASE SEVERITY; ELECTRIC FIELD; EPILEPTIC STATE; EXCITABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR CORTEX EXCITABILITY; MYOCLONUS EPILEPSY; NEUROANATOMY; NEURONAVIGATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RATING SCALE; SEIZURE THRESHOLD; TRANSCRANIAL MAGNETIC STIMULATION; UNIFIED MYOCLONUS RATING SCALE;

EPM1; PROGRESSIVE MYOCLONUS EPILEPSY; TRANSCRANIAL MAGNETIC STIMULATION MOTOR CORTEX; UNVERRICHT-LUNDBORG DISEASE;

ADULT; CYSTATIN B; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MOTOR CORTEX; MUTATION; SEVERITY OF ILLNESS INDEX; TRANSCRANIAL MAGNETIC STIMULATION; UNVERRICHT-LUNDBORG SYNDROME; YOUNG ADULT;

EID: 84887623518     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25615     Document Type: Article

References (59)

1. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005;4:239-248.
2. Leppik IE. Classification of the myoclonic epilepsies. Epilepsia. 2003;44(s11):2-6.
3. Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997;386:847-851.
4. Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet. 1997;15:393-396.
5. Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science. 1996;271:1731-1734.
6. Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand. 1974;50:307-332.
7. Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet. 1979;15:382-398.
8. Kälviäinen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia. 2008;49:549-556.
9. Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia. 2006;47:860-866.
10. Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve. 2005;31:157-174.
11. Cassim F, Houdayer E. Neurophysiology of myoclonus. Neurophysiol Clin. 2006;36:281-291.
12. Canafoglia L, Ciano C, Visani E, et al. Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Res. 2010;89:232-237.
13. Manganotti P, Tamburin S, Zanette G, Fiaschi A. Hyperexcitable cortical responses in progressive myoclonic epilepsy: a TMS study. Neurology. 2001;57:1793-1799.
14. Reutens DC, Puce A, Berkovic SF. Cortical hyperexcitability in progressive myoclonus epilepsy: a study with transcranial magnetic stimulation. Neurology. 1993;43:186-192.
15. Danner N, Julkunen P, Khyuppenen J, et al. Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1). Epilepsy Res. 2009;85:81-88.
16. Valzania F, Strafella AP, Tropeani A, Rubboli G, Nassetti SA, Tassinari CA. Facilitation of rhythmic events in progressive myoclonus epilepsy: a transcranial magnetic stimulation study. Clin Neurophysiol. 1999;110:152-157.
17. Danner N, Säisänen L, Määttä S, et al. Motor cortical plasticity is impaired in Unverricht-Lundborg disease. Mov Disord. 2011;26:2095-2100.
18. Koskenkorva P, Khyuppenen J, Niskanen E, et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology. 2009;73:606-611.
19. Koskenkorva P, Niskanen E, Hyppönen J, et al. Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis. AJNR Am J Neuroradiol. 2012;33:878-883.
20. Säisänen L, Julkunen P, Niskanen E, et al. Motor potentials evoked by navigated transcranial magnetic stimulation in healthy subjects. J Clin Neurophysiol. 2008;25:367-372.
21. Frucht SJ, Leurgans SE, Hallett M, Fahn S. The Unified Myoclonus Rating Scale. Adv Neurol. 2002;89:361-376.
22. Danner N, Könönen M, Säisänen L, Laitinen R, Mervaala E, Julkunen P. Effect of individual anatomy on resting motor threshold--computed electric field as a measure of cortical excitability. J Neurosci Methods. 2012;203:298-304.
23. Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage. 2005;24:163-173.
24. Mazziotta J, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001;356:1293-1322.
25. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87-97.
26. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143-155.
27. Tohka J, Zijdenbos A, Evans A. Fast and robust parameter estimation for statistical partial volume models in brain MRI. Neuroimage. 2004;23:84-97.
28. Kim JS, Singh V, Lee JK, et al. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage. 2005;27:210-221.
29. Chung MK, Taylor J.Diffusion smoothing on brain surface via finite element method. IEEE International Symposium on Biomedical Engineering: From Nano to Macro. 2004;1:432-435.
30. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120:2008-2039.
31. Julkunen P, Säisänen L, Sarasti M, Könönen M. Effect of electrode cap on measured cortical motor threshold. J Neurosci Methods. 2009;176:225-229.
32. Säisänen L, Pirinen E, Teitti S, et al. Factors influencing cortical silent period: optimized stimulus location, intensity and muscle contraction. J Neurosci Methods. 2008;169:231-238.
33. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870-878.
34. Cohen NR, Hammans SR, Macpherson J, Nicoll JA. New neuropathological findings in Unverricht-Lundborg disease: neuronal intranuclear and cytoplasmic inclusions. Acta Neuropathol. 2011;121:421-427.
35. Lefaucheur JP. Myoclonus and transcranial magnetic stimulation. Neurophysiol Clin. 2006;36:293.
36. McConnell KA, Nahas Z, Shastri A, et al. The transcranial magnetic stimulation motor threshold depends on the distance from coil to underlying cortex: a replication in healthy adults comparing two methods of assessing the distance to cortex. Biol Psychiatry. 2001;49:454-459.
37. Cantello R, Civardi C, Varrasi C, et al. Excitability of the human epileptic cortex after chronic valproate: a reappraisal. Brain Res. 2006;1099:160-166.
38. Reis J, Tergau F, Hamer HM, et al. Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia. 2002;43:1149-1156.
39. Epstein CM, Girard-Siqueira L, Ehrenberg JA. Prolonged neurophysiologic effects of levetiracetam after oral administration in humans. Epilepsia. 2008;49:1169-1173.
40. Manganotti P, Bongiovanni LG, Zanette G, Turazzini M, Fiaschi A. Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. Epilepsia. 1999;40:316-321.
41. Ziemann U. TMS and drugs. Clin Neurophysiol. 2004;115:1717-1729.
42. Reutens DC, Berkovic SF, Macdonell RA, Bladin PF. Magnetic stimulation of the brain in generalized epilepsy: reversal of cortical hyperexcitability by anticonvulsants. Ann Neurol. 1993;34:351-355.
43. Li X, Ricci R, Large CH, Anderson B, Nahas Z, George MS. Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability. J Neural Transm. 2009;116:423-429.
44. Zunhammer M, Langguth B, Landgrebe M, et al. Modulation of human motor cortex excitability by valproate. Psychopharmacology (Berl). 2011;215:277-280.
45. Inghilleri M, Gilio F, Conte A, et al. Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation. Exp Brain Res. 2006;174:667-672.
46. Reis J, Wentrup A, Hamer HM, et al. Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function-a TMS study. Epilepsy Res. 2004;62:41-51.
47. Solinas C, Lee YC, Reutens DC. Effect of levetiracetam on cortical excitability: a transcranial magnetic stimulation study. Eur J Neurol. 2008;15:501-505.
48. Inghilleri M, Berardelli A, Cruccu G, Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol. 1993;466:521-534.
49. Kimiskidis VK, Papagiannopoulos S, Sotirakoglou K, Kazis DA, Kazis A, Mills KR. Silent period to transcranial magnetic stimulation: construction and properties of stimulus-response curves in healthy volunteers. Exp Brain Res. 2005;163:21-31.
50. Badawy RA, Macdonell RA, Jackson GD, Berkovic SF. Can changes in cortical excitability distinguish progressive from juvenile myoclonic epilepsy? Epilepsia. 2010;51:2084-2088.
51. Buzzi A, Chikhladze M, Falcicchia C, et al. Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiol Dis. 2012;47:216-224.
52. Canafoglia L, Ciano C, Panzica F, et al. Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. Neurology. 2004;63:2309-2315.
53. Mascalchi M, Michelucci R, Cosottini M, et al. Brainstem involvement in Unverricht-Lundborg disease (EPM1): An MRI and 1H MRS study. Neurology. 2002;58:1686-1689.
54. Korja M, Kaasinen V, Lamusuo S, Parkkola R, Nagren K, Marttila RJ. Substantial thalamostriatal dopaminergic defect in Unverricht-Lundborg disease. Epilepsia. 2007;48:1768-1773.
55. Mervaala E, Andermann F, Quesney LF, Krelina M. Common dopaminergic mechanism for epileptic photosensitivity in progressive myoclonus epilepsies. Neurology. 1990;40:53-56.
56. Silen T, Forss N, Salenius S, Karjalainen T, Hari R. Oscillatory cortical drive to isometrically contracting muscle in Unverricht-Lundborg type progressive myoclonus epilepsy (ULD). Clin Neurophysiol. 2002;113:1973-1979.
57. Visani E, Agazzi P, Canafoglia L, et al. Movement-related desynchronization-synchronization (ERD/ERS) in patients with Unverricht-Lundborg disease. Neuroimage. 2006;33:161-168.
58. Visani E, Canafoglia L, Rossi Sebastiano D, et al. Giant SEPs and SEP-recovery function in Unverricht-Lundborg disease. Clin Neurophysiol. 2013;124:1013-1018.
59. Visani E, Minati L, Canafoglia L, et al. Simultaneous EEG-fMRI in patients with Unverricht-Lundborg disease: event-related desynchronization/synchronization and hemodynamic response analysis. Comput Intell Neurosci. 2010:164278.